On July 28, 2025, Celcuity Inc. reported positive results from their Phase 3 clinical trial for gedatolisib, showing a significant improvement in progression-free survival for breast cancer patients. The gedatolisib triplet reduced disease progression risk by 76%, achieving a median progression-free survival of 9.3 months compared to 2.0 months with standard treatment.